Join in, to hear Dr Jesse Boehm discuss the convergence of advancements that are making precision medicine more effective for a larger percentage of patients. He touches on how access to molecular profiling has become more widespread and affordable, allowing more patients to get detailed molecular information about their tumors. Dr. Boehm then mentions how new types of chemistry and drug development are making it possible to target a wider range of cancer proteins. He goes on to describe how innovations in biopsies enable real-time monitoring of tumors, providing a comprehensive molecular portrait of the tumor’s evolution. Overall, Dr. Boehm is optimistic that these and the other advancements that he discusses will significantly improve the outcome for most cancer patients within the next few decades.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related